Under healthy physiologic conditions epithelium of the lungs undergo constant renewal due to activity of the adult stem cells of the lungs. These cells are also responsible for regeneration of the tissues of the lungs after the injury.
However, if the injury is too severe or chronic, regeneration potential of the innate adult stem cells of the lungs of the patient could be exhausted. Especially if the onset of the disease occurs in older age, when activity of adult stem cells is decreased. Chronic inflammation in combination with insufficient regeneration considered to play important role in the development of such life-threatening pulmonary disease as idiopathic pulmonary fibrosis (IPF).
Scientists and doctors of the Infinity Clinic have developed comprehensive approach for the treatment of IPF based on administration of organ-specific fetal stem cells of the lungs. These cells are able to migrate into the damaged areas of the lungs, integrate into the basal membrane and give rise to the new epithelial cells of the lungs. Hence substituting damaged and dying cells of the patient. Additionally, fetal stem cells of the lungs produce and release anti-inflammatory mediators that suppress chronic inflammation. Also, these cells release variety of trophic factors and exosomes that stimulate regeneration of the tissues. Efficiency of this method was proven by the results of our patients presented in the figures 1,2,3.
Figure 1. Shows significant improvement in the bold oxygenation (saturation) at rest. Box plots illustrating distributions of the level of saturation (n=5 patients). Each marker represents results of the particular patient studied before the treatment, 6 months after and 12 months after the treatment.
Figure 2. Shows significant improvement in the bold oxygenation (saturation) after 6-minutes’ walk. Box plots illustrating distributions of the level of saturation (n=5 patients). Each marker represents results of the particular patient studied before the treatment, 6 months after and 12 months after the treatment.
Figure 3. Shows significant improvement according to the Borg dyspnea scale. Box plots illustrating distributions of the scores of the Borg dyspnea scale (n=5 patients). Each marker represents results of the particular patient studied before the treatment, 6 months after and 12 months after the treatment.
Thus, organ-specific fetal stem cell therapy represents efficient approach for the treatment of the idiopathic pulmonary fibrosis, and mission of our clinic is to use healing potential of the fetal stem cells in order to improve health of our patients.
